

1956: The first NCI-sponsored multi-institutional cancer clinical trial

10-1
PRIVILEGED COMMUNICATION -
FOR ADMINISTRATIVE USE ONLY

Acute Leukemia
Cooperative Group B
Clinical Director, NCI -
Bldg. 10, Room 10-N-113

Secretary's Office
Acute Leukemia Coop. Group B
NIH Bldg. 10, Rm. 1B-47A
Bethesda 14, Maryland

Protocol #1

PROTOCOL FOR A
COOPERATIVE STUDY IN THE CHEMOTHERAPY
OF ACUTE LEUKEMIA

PARTICIPATING HOSPITAL AND RESPONSIBLE INVESTIGATORS

National Cancer Institute
National Institutes of Health
Bethesda 14, Maryland

Emil Frei, M.D.

Roswell Park Memorial Institute
Buffalo 3, New York

James F. Holland

Department of Pediatrics
Children's Hospital
Buffalo, New York

George Selkirk, M.D.

A Comparative Study of Two Regimens of Combination Chemotherapy in Acute Leukemia

By EMIL FREI, III, JAMES F. HOLLAND, MARVIN A. SCHNEIDERMAN,
DONALD PINKEL, GEORGE SELKIRK, EMIL J. FREIREICH, RICHARD T. SILVER,
G. LENNARD GOLD AND WILLIAM REGELSON





FIG. 2.—Duration of survival from start of combined therapy.

TODAY'S RESEARCH CHALLENGES.....

Total cancer mortality: by sex, 1950-2000



A NATIONAL CANCER CLINICAL TRIALS SYSTEM FOR THE 21ST CENTURY

Reinvigorating the NCI Cooperative Group Program

Articles from the *New England Journal of Medicine* Genomic Medicine





Edited by
ALAN E. GUTTMACHER, M.D.
FRANCIS S. COLLINS, M.D., Ph.D.
JEFFREY M. DRAZEN, M.D.

With a Foreword by
HAS ZERHOUNI, M.D.

HEALTHCARE
IS A
CIVIL
RIGHT


Health Care Politics
Today's Headlines





THE CANCER GENOME ATLAS 

Research Changing Patient Care



Genomewide
Association
Studies



Clinical
Outcomes
Databases



Adaptive
Trial
Designs



Functional
Imaging




Outcome-
linked
Biorepositories



"If you're a mouse with cancer, we can take good care of you - unfortunately people with cancer present a bigger challenge."

Judah Folkman




III


II

PHASE I

**LABORATORY
RESEARCH**




Institute of Medicine Consensus Committee Report: April 2010



“Declining funding, inefficient processes, extensive and complex government oversight and a lack of resources to pursue cutting-edge research hinder the Cooperative Group Program’s ability to translate research discoveries into timely clinical applications.”

“...a crisis...”

Recommendations



1. Improve the speed and efficiency of design, launch, and conduct of clinical trials
2. Incorporate innovative science and trial designs into cancer clinical trials
3. Improve the means of prioritization, selection, support and completion of cancer clinical trials
4. Incentivize the participation of patients and physicians in clinical trials

Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop #2

Session 1. Updates from NCI and NCTN Components: Progress Report

Session 4. The NCTN as a Platform to Implement Precision Medicine

Session 2. Funding for Cancer Clinical Trials

Session 5. Accelerating Innovation Through Effective Partnerships

Session 3. Prioritization of Publicly-Funded Trials

Session 6. Regulatory Issues